Log in

CNSX:ATTAbattis Bioceuticals Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.42 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers—Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-3360881

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ATT News and Ratings via Email

Sign-up to receive the latest news and ratings for ATT and its competitors with MarketBeat's FREE daily newsletter.

Abattis Bioceuticals (CNSX:ATT) Frequently Asked Questions

Has Abattis Bioceuticals been receiving favorable news coverage?

News headlines about ATT stock have trended very positive this week, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Abattis Bioceuticals earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutAbattis Bioceuticals.

Who are some of Abattis Bioceuticals' key competitors?

What other stocks do shareholders of Abattis Bioceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abattis Bioceuticals investors own include Aphria (APHA), Surna (SRNA), CannTrust (CTST), HEXO (HEXO), Canopy Growth (WEED), Aurora Cannabis (ACBFF), Aurora Cannabis (ACB), Laird (LRD), MedReleaf (LEAF) and Hays (HAS).

Who are Abattis Bioceuticals' key executives?

Abattis Bioceuticals' management team includes the following people:
  • Robert Abenante CPA, President, Chief Executive Officer, Director (Age 33)
  • David Whitney, Chief Financial Officer
  • Rene David, Chief Operating Officer, Director
  • Christopher P. Cherry, Corporate Controller (Age 40)
  • Hugh Oswald, IR Contact Officer
  • Christina Boddy, Corporate Secretary
  • Peter Gordon, Director
  • James Irving, Director
  • Shuang Xie, Director
  • Guy P. Dancosse QC, Independent Director

What is Abattis Bioceuticals' stock symbol?

Abattis Bioceuticals trades on the CNSX under the ticker symbol "ATT."

What is Abattis Bioceuticals' official website?

The official website for Abattis Bioceuticals is www.abattis.com.

How can I contact Abattis Bioceuticals?

Abattis Bioceuticals' mailing address is 224-970 Burrard St, VANCOUVER, BC V6Z 2R4, Canada. The company can be reached via phone at +1-604-3360881.

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.